News for Adaptimmune Therapeutics plc (ADAP)

PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (”œContext” or ”œCompany”) ( CNTX), a clinical-stage biopharmaceutical company

In recent analyst activity, Barclays has maintained its "Underweight" rating on Adaptimmune Therapeutics (ADAP). Despite retaining the same rating, the financia

On May 14, 2025, Wells Fargo analyst Yanan Zhu made a significant update regarding Adaptimmune Therapeutics (ADAP). The analyst maintained an 'Equal-Weight' rat

Wells Fargo has revised its price target for Adaptimmune (ADAP), cutting it to $1 from the previous $1.50, while maintaining an Equal Weight rating on the stock

Revenue Guidance: Full-year Tecelra sales projected between $35 million and $45 million.Net Sales for Q1 2025: $4 million from Tecelra treatments.Tecelra Treat

May 13, 2025 / 12:00PM GMTOperator Hello and welcome to Adaptimmune's first-quarter 2025 business update conference call. (Operator Instructions) the conference

Adaptimmune Therapeutics PLC (ADAP) is set to release its Q1 2025 earnings on May 13, 2025. The consensus estimate for Q1 2025 revenue is $6.17 million, and the

JonesResearch has revised its rating for Adaptimmune (ADAP), moving it from a Buy to a Hold. This adjustment reflects ongoing concerns about the company's capit

Operator: Hello, and welcome to the Adaptimmune's Q4 and Full Year 2024 Business Update Conference Call. As a reminder, all participants are in a listen-only mode. The conference is being recorded.

Adaptimmune Therapeutics PLC (ADAP) is set to release its Q4 2024 earnings on Mar 20, 2025. The consensus estimate for Q4 2024 revenue is $5.83 million, and the

Q4 2024 Product Revenue: $1.2 million from Tecelra sales.Authorized Treatment Centers (ATCs): 20 ATCs established, representing 2/3 of the planned network.Pati

Mar 20, 2025 / 12:00PM GMTOperator Hello and welcome to the Adaptimmune Q4 and full year 2024 business update conference call. (Operator Instructions) I wound n

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2024 Earnings Conference Call March 20, 2025 8:00 AM ETCompany ParticipantsJuli Miller - IRAdrian Rawcliffe -...

U.S. stocks traded higher this morning, with the Dow Jones index gaining over 100 points on Thursday. Following the market opening Thursday, the Dow traded up ...

Revenue: Q4 product revenue of $1.2 million, with 2 patients invoiced.Total Liquidity: $152 million at the end of 2024, providing a strong financial position.P

On December 31, 2024, Two Seas Capital LP (Trades, Portfolio) executed a noteworthy transaction by acquiring 89,010,876 shares of Adaptimmune Therapeutics PLC.

Significant Transaction by Baillie Gifford (Trades, Portfolio) On December 31, 2024, Baillie Gifford (Trades, Portfolio) executed a noteworthy transaction by si

Adaptimmune therapeutics' chief medical officer sells $3,243 in stock

Adaptimmune therapeutics CEO Adrian Rawcliffe sells shares worth $34,639